Compare Bristol-Myers Squibb Co (BMY) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Wheaton Precious Metals Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.66 (market cap $129.94B), while Wheaton Precious Metals Corp trades at $135.66 (market cap $60.94B). The key difference: Bristol-Myers Squibb Co is far larger — about 2.1× Wheaton Precious Metals Corp's market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | WPM | |
|---|---|---|
Market Cap | $129.94B | $60.94B |
Sector | Health | Basic Materials |
52-Week High | $65.89 | $165.72 |
52-Week Low | $42.60 | $91.02 |
Enterprise Value | $163.92B | $62.82B |
Dividend Yield | 3.96% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.83, down 1.56% today, with strong technical bullish signals and consistent earnings beats. The stock shows robust fundamentals with a 14.01 P/E ratio, 18.87% net margin, and recent $2.3 billion manufacturing investment. Analyst consensus leans neutral with a $68.56 price target, while technical indicators suggest bullish momentum with key support at $63.
BMY presents a balanced opportunity with strong profitability and growth pipeline offset by patent expiration risks. The stock's current valuation appears reasonable with upside potential to analyst targets, though investors should monitor debt levels and competitive pressures in the pharmaceutical sector.
Wheaton Precious Metals (WPM) trades at $133.39, down 0.6% for the day, with a bullish technical signal driven by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.19, supported by higher metal prices and sales volumes. Revenue surged to $2.31 billion in 2025, with net income reaching $1.47 billion, reflecting robust profitability margins.
The outlook remains positive with an 80% analyst buy rating and a $161.75 consensus price target, indicating ~21% upside. Key risks include reliance on commodity prices and projected negative cash flow in 2026. The stock's premium valuation (P/E 29.82) requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
